Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs
This article was originally published in The Pink Sheet Daily
Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.
You may also be interested in...
$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.
California Supreme Court finds patents are ‘probablistic rather than ironclad,’ and outlines four-prong antitrust test that further complicates brand/generic deal making.
Teva plays it safe in $512 million agreement with direct purchasers, even though AstraZeneca won a jury verdict in similar suit, the first to go to trial since Supreme Court’s FTC v. Actavis decision.